ALP Bio

ALP Bio
Combines human immune organoid biology with generative AI to reduce immunogenicity risk in antibody development.
About
What does ALP Bio do?
ALP Bio AG is a Swiss biotech startup developing a platform that integrates human immune organoid biology with generative AI. Their goal is to help antibody developers identify, understand, and reduce immunogenicity risk earlier in the drug development process. The platform leverages human tonsil organoid technology to model immune activity in vitro and employs AI models to learn from biological datasets. This hybrid approach aims to provide more clinically relevant signals for earlier decision-…
What is ALP Bio's revenue?
StartupHub estimates ALP Bio's annual revenue at $318K (range $109K to $928K, 34% confidence), based on comparable companies in the sector.
What is ALP Bio's valuation?
StartupHub estimates ALP Bio's effective valuation at $8.1M (range $5.2M to $12.5M, 24% confidence), based on comparable companies in the sector.
How much funding has ALP Bio raised?
ALP Bio has raised a total of $2M in funding. The most recent round on record is Pre-Seed.
Where is ALP Bio headquartered?
ALP Bio is headquartered in Schlieren, Zurich, Switzerland.
When was ALP Bio founded?
ALP Bio was founded in 2025.
What industry does ALP Bio operate in?
ALP Bio operates in Biotechnology, Artificial Intelligence, Drug Discovery, Pharmaceuticals, Biotech, AI-Driven Drug Discovery.
No comments yet. Be the first to share your take.